CF10/LV overcomes acquired resistance to 5-FU/LV in colorectal cancer cells through downregulation of the c-Myc/ABCB5 axis

Abstract

Aim: Acquired resistance to 5-fluorouracil/leucovorin (5-FU/LV) frequently develops during treatment of metastatic colorectal (mCRC), but the causes are incompletely understood. We aim to: (i) identify the causes of 5-FU/LV resistance under physiological folate; and (ii) determine if a polymeric fluoropyrimidine (FP) CF10 remains potent to CRC cells selected for 5-FU/LV resistance.

Methods: 5-FU/LV-resistant CRC cells were selected by repeated passaging with increasing 5-FU/LV concentrations, and resistance factors were calculated from dose-response studies. Basal and treatment-induced thymidylate synthase (TS), Myc, and ABCB5 were determined by RT-qPCR and Western blot. TS activity was determined using an in situ ³H-release assay. DNA topoisomerase 1 cleavage complexes (Top1cc) and DNA double-strand breaks (DSBs) were determined by immunofluorescence.

Results: Acquired resistance to 5-FU/LV with physiological folate was associated with a <1.5-fold increase in basal TS levels; however, with either 5-FU/LV or CF10/LV treatment, TS levels were elevated ~5-fold by Western blot but only ~2-fold by RT-qPCR. CF10 remained very potent to CRC cells selected for 5-FU/LV resistance, and CF10 effectively induced TS ternary complex formation and inhibited TS catalytic activity in 5-FU/LV-resistant CRC cells. c-Myc was expressed at ~4-fold higher levels in 5-FU/LV-resistant CRC cells, but Myc was barely detectable with CF10/LV treatment. The Myc-target ABCB5, which is an established factor in resistance to 5-FU and other drugs, was substantially downregulated with CF10/LV but not 5-FU/LV treatment.

Conclusion: Acquired 5-FU/LV resistance was associated with FP-induced TS and elevated Myc and ABCB5. There is minimal cross-resistance to CF10 in 5-FU/LV-resistant CRC cells, consistent with its use in treating 5-FU/LV-resistant mCRC.

Keywords

Fluoropyrimidine / thymidylate synthase / DNA Topoisomerase 1 / Myc / ABCB5 / CF10

References

[1] Gmeiner WH.Recent advances in therapeutic strategies to improve colorectal cancer treatment.Cancers2024;16:1029 PMCID:PMC10930828

[2] Gmeiner WH.Review of 5-FU resistance mechanisms in colorectal cancer: clinical significance of attenuated on-target effects.Cancer Drug Resist2023;6:257-72 PMCID:PMC10344727

[3] Rumpold H,Heiler C.Prediction of mortality in metastatic colorectal cancer in a real-life population: a multicenter explorative analysis.BMC Cancer2020;20:1149 PMCID:PMC7691098

[4] Gmeiner WH.Chemistry of fluorinated pyrimidines in the era of personalized medicine.Molecules2020;25:3438 PMCID:PMC7435603

[5] Wilson PM,Johnston PG,Ladner RD.Standing the test of time: targeting thymidylate biosynthesis in cancer therapy.Nat Rev Clin Oncol2014;11:282-98

[6] Sen A.An insight into thymidylate synthase inhibitor as anticancer agents: an explicative review.Naunyn Schmiedebergs Arch Pharmacol2024;397:5437-48

[7] Gmeiner WH.Novel chemical strategies for thymidylate synthase inhibition.Curr Med Chem2005;12:191-202

[8] Santi DV,Raines RT.Kinetics and thermodynamics of the interaction of 5-fluoro-2′-deoxyuridylate with thymidylate synthase.Biochemistry1987;26:8606-13

[9] Diasio RB.Clinical pharmacology of 5-fluorouracil.Clin Pharmacokinet1989;16:215-37

[10] Patel K,Azad NA.A thymidylate synthase ternary complex-specific antibody, FTS, permits functional monitoring of fluoropyrimidines dosing.Oncotarget2012;3:678-85 PMCID:PMC3443251

[11] Yang C,Windle JJ,Moran RG.Humanizing mouse folate metabolism: conversion of the dual-promoter mouse folylpolyglutamate synthetase gene to the human single-promoter structure.FASEB J2014;28:1998-2008 PMCID:PMC3986845

[12] Epstein-Peterson ZD,Fenelus M.Folate testing and deficiency in hospitalized cancer patients.Blood2018;132:5814

[13] Sobral AF,Silva V,Silva R.Unveiling the therapeutic potential of folate-dependent one-carbon metabolism in cancer and neurodegeneration.Int J Mol Sci2024;25:9339 PMCID:PMC11395277

[14] Taflin H,Carlsson G.Increased potentiation of 5-fluorouracil induced thymidylate synthase inhibition by 5,10-methylenetetrahydrofolate (arfolitixorin) compared to leucovorin in patients with colorectal liver metastases; The Modelle-001 Trial.BJC Rep2024;2:89 PMCID:PMC11579015

[15] Danenberg PV,Johnston P.Folates as adjuvants to anticancer agents: chemical rationale and mechanism of action.Crit Rev Oncol Hematol2016;106:118-31

[16] Therizols G,Panthu B.Alteration of ribosome function upon 5-fluorouracil treatment favors cancer cell drug-tolerance.Nat Commun2022;13:173 PMCID:PMC8748862

[17] Mafi A,Milasi YE.The function and mechanism of circRNAs in 5-fluorouracil resistance in tumors: biological mechanisms and future potential.Pathol Res Pract2024;260:155457

[18] Barathan M,Ng SL,Ng MH.Innovative strategies to combat 5-fluorouracil resistance in colorectal cancer: the role of phytochemicals and extracellular vesicles.Int J Mol Sci2024;25:7470 PMCID:PMC11242358

[19] Matuszyk J.MALAT1-miRNAs network regulate thymidylate synthase and affect 5FU-based chemotherapy.Mol Med2022;28:89 PMCID:PMC9351108

[20] Mori R,Tokumaru Y,Futamura M.The mechanism underlying resistance to 5-fluorouracil and its reversal by the inhibition of thymidine phosphorylase in breast cancer cells.Oncol Lett2022;24:311 PMCID:PMC9353785

[21] Gmeiner WH,Haber AO.Improved antitumor activity of the fluoropyrimidine polymer CF10 in preclinical colorectal cancer models through distinct mechanistic and pharmacologic properties.Mol Cancer Ther2021;20:553-63 PMCID:PMC8201368

[22] Haber AO,Mani C.AraC-FdUMP[10] is a next-generation fluoropyrimidine with potent antitumor activity in PDAC and synergy with PARG inhibition.Mol Cancer Res2021;19:565-72 PMCID:PMC9013283

[23] Okechukwu CC,Sah N,Palle K.Enhanced therapeutic efficacy of the nanoscale fluoropyrimidine polymer CF10 in a rat colorectal cancer liver metastasis model.Cancers2024;16:1360 PMCID:PMC11011147

[24] Finan JM,Park SY.The polymeric fluoropyrimidine CF10 overcomes limitations of 5-FU in pancreatic ductal adenocarcinoma cells through increased replication stress.Cancer Biol Ther2024;25:2421584 PMCID:PMC11552260

[25] Liu J,Lawson TA.Targeted drug delivery to chemoresistant cells: folic acid derivatization of FdUMP[10] enhances cytotoxicity toward 5-FU-resistant human colorectal tumor cells.J Org Chem2001;66:5655-63

[26] Chu E.The role of thymidylate synthase as an RNA binding protein.Bioessays1996;18:191-8

[27] Chu E,Casey JL.Autoregulation of human thymidylate synthase messenger RNA translation by thymidylate synthase.Proc Natl Acad Sci U S A1991;88:8977-81 PMCID:PMC52634

[28] Chu E,Jones KL.Thymidylate synthase binds to c-myc RNA in human colon cancer cells and in vitro.Mol Cell Biol1995;15:179-85 PMCID:PMC231930

[29] McMahon SB.MYC and the control of apoptosis.Cold Spring Harb Perspect Med2014;4:a014407 PMCID:PMC4066641

[30] Kugimiya N,Hosoyama T.The c-MYC-ABCB5 axis plays a pivotal role in 5-fluorouracil resistance in human colon cancer cells.J Cell Mol Med2015;19:1569-81 PMCID:PMC4511355

[31] Gerard L.The uniqueness of ABCB5 as a full transporter ABCB5FL and a half-transporter-like ABCB5β.Cancer Drug Resist2024;7:29 PMCID:PMC11391348

[32] Wilson BJ,Zhan Q.ABCB5 identifies a therapy-refractory tumor cell population in colorectal cancer patients.Cancer Res2011;71:5307-16 PMCID:PMC3395026

[33] Blondy S,Verdier M,Perraud A.5-Fluorouracil resistance mechanisms in colorectal cancer: from classical pathways to promising processes.Cancer Sci2020;111:3142-54 PMCID:PMC7469786

[34] Copur S,Drake JC,Chu E.Thymidylate synthase gene amplification in human colon cancer cell lines resistant to 5-fluorouracil.Biochem Pharmacol1995;49:1419-26

[35] Peters GJ,Freemantle S.Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism.Biochim Biophys Acta2002;1587:194-205

[36] Fischel JL,Ciccolini J.Impact of the oxaliplatin-5 fluorouracil-folinic acid combination on respective intracellular determinants of drug activity.Br J Cancer2002;86:1162-8 PMCID:PMC2364172

[37] Zhu X,Gao Y.The feedback loop of EFTUD2/c-MYC impedes chemotherapeutic efficacy by enhancing EFTUD2 transcription and stabilizing c-MYC protein in colorectal cancer.J Exp Clin Cancer Res2024;43:7 PMCID:PMC10759692

[38] Patel AG,Peterson KL.Immunodetection of human topoisomerase I-DNA covalent complexes.Nucleic Acids Res2016;44:2816-26 PMCID:PMC4824114

[39] Peters GJ,Smid K,Jansen G.Determinants of activity of the antifolate thymidylate synthase inhibitors Tomudex (ZD1694) and GW1843U89 against mono- and multilayered colon cancer cell lines under folate-restricted conditions.Cancer Res1999;59:5529-35

[40] Liao ZY,Zhang HL.A novel polypyrimidine antitumor agent FdUMP[10] induces thymineless death with topoisomerase I-DNA complexes.Cancer Res2005;65:4844-51

[41] Gmeiner WH,Pommier Y.Genome-wide mRNA and microRNA profiling of the NCI 60 cell-line screen and comparison of FdUMP[10] with fluorouracil, floxuridine, and topoisomerase 1 poisons.Mol Cancer Ther2010;9:3105-14 PMCID:PMC3059097

[42] Very N,Decourcelle A.Thymidylate synthase O-GlcNAcylation: a molecular mechanism of 5-FU sensitization in colorectal cancer.Oncogene2022;41:745-56

[43] Das SK,Venkatachalapathy H,Batchelor E.Excessive MYC-topoisome activity triggers acute DNA damage, MYC degradation, and replacement by a p53-topoisome.Mol Cell2024;84:4059-78.e10 PMCID:PMC11560571